Log in to search using one of your social media accounts:

 

Age and gut bacteria contribute to MS disease progression, according to Rutgers
(Rutgers University) Gut bacteria at a young age can contribute to multiple sclerosis disease onset and progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2017 Category: International Medicine & Public Health Source Type: news

Social care failing people with disabilities, says leading charity
Young people with MS forced to live in care homes for older people Related items fromOnMedica Social care set to eat up over half of council tax receipts by 2020 A clinical review of multiple sclerosis 'Homes not hospitals ’ for people with learning disability Diabetics likely to have much fewer disability-free years Health professionals vary hugely in disability assessments (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 15, 2017 Category: UK Health Source Type: news

Sex differences a rich field for UCLA multiple sclerosis researcher
As a child, Dr. Rhonda Voskuhl had terrible asthma, was often sick and had to get weekly allergy shots. She wondered why her body was so reactive to pollen, cats, wheat and eggs — her throat would swell, breathing became more difficult and her skin developed a rash. A frequent visitor to the doctor’s office, she had “a wonderful doctor who made me feel so much better.”It ’s no surprise, then, that Voskuhl grew up to become a doctor. Today, Voskuhl directs UCLA’s multiple sclerosis program and is the Jack H. Skirball professor of Multiple Sclerosis Research. She’s wrapping up one cl...
Source: UCLA Newsroom: Health Sciences - November 13, 2017 Category: Universities & Medical Training Source Type: news

Prediction of falls in subjects suffering from Parkinson's disease, multiple sclerosis and stroke - Beghi E, Gervasoni E, Pupillo E, Bianchi E, Montesano A, Aprile I, Agostini M, Rovaris M, Cattaneo D.
OBJECTIVE: To compare the risk of falls and fall predictors in patients with Parkinson's disease (PD), multiple sclerosis (MS) and stroke using the same study design. DESIGN: Multicenter prospective cohort study. SETTING: Three [masked] institution... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Ocrelizumab (Ocrevus) Gets CHMP Nod for Multiple Sclerosis Ocrelizumab (Ocrevus) Gets CHMP Nod for Multiple Sclerosis
The EMA committee recommends ocrelizumab for adults with relapsing multiple sclerosis and early primary progressive multiple sclerosis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Roche MS drug Ocrevus wins European panel backing
ZURICH (Reuters) - Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year. (Source: Reuters: Health)
Source: Reuters: Health - November 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche ’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for people with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. (Source: Roche Media News)
Source: Roche Media News - November 10, 2017 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for people with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. (Source: Roche Investor Update)
Source: Roche Investor Update - November 10, 2017 Category: Pharmaceuticals Source Type: news

Two new treatments become available on the NHS
Hundreds of patients with multiple sclerosis are set to benefit from a new treatment option, Mavenclad, following a deal with drug company Merck. (Source: NHS Networks)
Source: NHS Networks - November 10, 2017 Category: UK Health Source Type: news

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years DARMSTADT, Ge... Biopharmaceuticals, Neurology, Regulatory Merck, Cladribine, MAVENCLAD, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Sanofi, Principia agree to develop multiple sclerosis drug candidate
Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling. (Source: World Pharma News)
Source: World Pharma News - November 9, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Ozanimod successful in clinical trials for multiple sclerosis
(Scripps Research Institute) Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod. Ozanimod was invented by scientists at The Scripps Research Institute (TSRI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2017 Category: International Medicine & Public Health Source Type: news

MMJ BioScience Proceeding with FDA Multiple Sclerosis Clinical Trial...
The MMJ BioScience team will be carefully conducting these controlled clinical studies to determine the benefits and risks of medical marijuana products for safe patient use.(PRWeb November 08, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14899386.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 8, 2017 Category: Pharmaceuticals Source Type: news

Aspirin May Improve Exercise Endurance in MS Aspirin May Improve Exercise Endurance in MS
A small pilot study suggests aspirin may be an'easy, economical'treatment to minimize overheating with exertion and allow patients with multiple sclerosis to get the benefits of exercise.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 7, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Two Phase 3 Trials Show Ozanimod Effective in Relapsing MS Two Phase 3 Trials Show Ozanimod Effective in Relapsing MS
On the basis of full SUNBEAM and RADIANCE results, showing ozanimod reduces relapses and lesions in patients with relapsing multiple sclerosis, regulatory submissions will soon be filed in the United States and European Union.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

For Canadians in queue for long-term care spots, waiting costs 'astronomical'
The younger sisters of a Nova Scotia woman with epilepsy and multiple sclerosis say the costs of waiting to get her into a nursing home are hard for them to bear. (Source: CBC | Health)
Source: CBC | Health - November 6, 2017 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news

Scratching the surface of mature monocytes...and coming up with CXCR7
(Federation of American Societies for Experimental Biology) New research published online in the Journal of Leukocyte Biology showed for the first time that mature monocytes (a specific type of white blood cell) express the CXCR7 receptor on their surface. This receptor may be a therapeutic target for controlling inflammation in the brain associated with diseases like multiple sclerosis, Parkinson's and AIDS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2017 Category: International Medicine & Public Health Source Type: news

Teva warns on profit as drugmaker's problems deepen
JERUSALEM (Reuters) - Teva Pharmaceutical Industries, the world's biggest generic medicine maker, said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of its multiple sclerosis drug Copaxone, hammering its shares (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Impressive Results With Fingolimod in Pediatric MS Impressive Results With Fingolimod in Pediatric MS
In the first randomized trial in pediatric multiple sclerosis, fingolimod was associated with sizable reductions in relapse rate, new MRI lesions, brain atrophy, and disability progression compared with interferon beta.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Free iPhone App could Guide MS Research, Treatment
For some diseases, a simple blood test is all that's needed to estimate severity or confirm a diagnosis. Not so for multiple sclerosis. No single lab test can tell doctors what type of MS a patient has, nor whether it's responding to treatment. But by better tracking patients' symptoms and potential triggers with help from a new iPhone app, (Source: eHealth News EU)
Source: eHealth News EU - October 31, 2017 Category: Information Technology Tags: Featured Research Research and Development Source Type: news

Study identifies new biomarker for multiple sclerosis
Researchers at the University of Sydney have uncovered a new, powerful biomarker in the blood of patients with multiple sclerosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 30, 2017 Category: Consumer Health News Source Type: news

Falls among full-time wheelchair users with spinal cord injury and multiple sclerosis: a comparison of characteristics of fallers and circumstances of falls - Sung J, Trace Y, Peterson EW, Sosnoff JJ, Rice LA.
PURPOSE: The purpose of this study is to (1) explore and (2) compare circumstances of falls among full-time wheelchair users with spinal cord injury (SCI) and multiple sclerosis (MS). METHODS: A mixed method approach was used to explore and compare... (Source: SafetyLit)
Source: SafetyLit - October 30, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

New MS Diagnostic Criteria Will Allow Earlier Diagnosis New MS Diagnostic Criteria Will Allow Earlier Diagnosis
The updated McDonald criteria allow CSF findings and symptomatic MRI lesions to be considered for the diagnosis of multiple sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting in Paris, France. (Source: Roche Media News)
Source: Roche Media News - October 27, 2017 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting in Paris, France. (Source: Roche Investor Update)
Source: Roche Investor Update - October 27, 2017 Category: Pharmaceuticals Source Type: news

Data from Wearable Biosensors Correlates with Multiple Sclerosis Disease Severity in Pilot Study
Findings suggest that wearable sensors could provide valuable indicators of disease status (Source: BWH News)
Source: BWH News - October 27, 2017 Category: Hospital Management Source Type: news

Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. This year, 77 proposals from 25 countries were submitted, representing innovative research projects taking place across the globe. (Source: World Pharma News)
Source: World Pharma News - October 26, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Ex-policewoman's cannabis use to relieve pain from MS
Ex-policewoman Sue Cox smokes cannabis to relieve the pain of crippling multiple sclerosis. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 25, 2017 Category: Consumer Health News Source Type: news

Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting (October 25-28, 2017 Paris, France). (Source: World Pharma News)
Source: World Pharma News - October 25, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Exciting new breakthrough could lead to a cure for multiple sclerosis
(Natural News) A recent study published in the Journal of Neuroinflammation revealed a mechanism that may one day help identify the root cause of multiple sclerosis, and develop long-overdue treatments for the disease. As part of the study, a team of international researchers from the University of Exeter in the U.K. and the University of Alberta in Canada examined brain... (Source: NaturalNews.com)
Source: NaturalNews.com - October 25, 2017 Category: Consumer Health News Source Type: news

BIOCAD enters the European market
The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. This are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis. (Source: World Pharma News)
Source: World Pharma News - October 25, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes
Ask About Adherence is a blog series featuring Q&A ’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and injectable disease-modifying therapies for patients with multiple sclerosis. (Source: The Catalyst)
Source: The Catalyst - October 24, 2017 Category: Pharmaceuticals Tags: chronic disease Multiple Sclerosis Ask About Adherence Source Type: news

Predicting falls among patients with multiple sclerosis: Comparison of patient-reported outcomes and performance-based measures of lower extremity functions - Tajali S, Shaterzadeh-Yazdi MJ, Negahban H, van Dieen JH, Mehravar M, Majdinasab N, Saki-Malehi A, Mofateh R.
BACKGROUND: Accurate fall screening tools are needed to identify those multiple sclerosis (MS) patients at high risk of falling. The present study aimed at determining the validity of a series of performance-based measures (PBMs) of lower extremity functio... (Source: SafetyLit)
Source: SafetyLit - October 24, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Systematic review of depression in patients with multiple sclerosis and its relationship to interferon β treatment - Alba Palé L, León Caballero J, Samsó Buxareu B, Salgado Serrano P, Perez Sola V.
BACKGROUND: Multiple sclerosis is a chronic disease considered the major cause of neurological disability in young adults worldwide. While depression is considered a determinant factor of impaired quality of life and poorer prognosis among patients with mu... (Source: SafetyLit)
Source: SafetyLit - October 24, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Paul Tesar receives 2017 New York Stem Cell Foundation -- Robertson Stem Cell Prize
(New York Stem Cell Foundation) The New York Stem Cell Foundation (NYSCF) announced today that Paul Tesar, DPhil, is the 2017 recipient of the NYSCF -- Robertson Stem Cell Prize for his pioneering discovery of pluripotent epiblast stem cells and technologies to utilize pluripotent stem cells for discovery of new therapeutics for neurological disorders such as multiple sclerosis and pediatric leukodystrophies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells
A lack of regulatory T cell function is a critical factor in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). Ligation of the complement regulatory protein CD46 facilitates the differentiation of T helper 1 (TH1) effector cells into interleukin-10 (IL-10)–secreting type 1 regulatory T cells (Tr1 cells), and this pathway is defective in MS patients. Cleavage of the ectodomain of CD46, which contains three N-glycosylation sites and multiple O-glycosylation sites, enables CD46 to activate T cells. We found that stimulation of the T cell receptor (TCR)–CD3 complex was associated with a redu...
Source: Signal Transduction Knowledge Environment - October 24, 2017 Category: Science Authors: Ni Choileain, S., Hay, J., Thomas, J., Williams, A., Vermeren, M. M., Benezech, C., Gomez-Salazar, M., Hugues, O. R., Vermeren, S., Howie, S. E. M., Dransfield, I., Astier, A. L. Tags: STKE Research Articles Source Type: news

Boost for lipid research: Austrian researchers facilitate lipid data analysis
(Graz University of Technology) Illnesses such as cancer and multiple sclerosis may also be associated with lipids. Disorders are difficult to assess due to the diversity of lipids. Austrian scientists from Graz present a new tool for the analysis of lipids in Nature Methods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2017 Category: Cancer & Oncology Source Type: news

When Someone You Love Has Multiple Sclerosis
Get tips on how on how to be a caregiver for a friend or relative who has multiple sclerosis (MS). (Source: WebMD Health)
Source: WebMD Health - October 20, 2017 Category: Consumer Health News Source Type: news

OHSU's Robertson on coming to grips with his diagnosis
After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other decision he could make. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 19, 2017 Category: Health Management Authors: Elizabeth Hayes Source Type: news

OHSU's Robertson on coming to grips with his diagnosis
After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other decision he could make. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2017 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Concussion in teens increase risk of multiple sclerosis
Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They found adolescents who had a concussion increased their risk by 22 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2017 Category: Consumer Health News Source Type: news

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple sclerosis. (Source: NYT Health)
Source: NYT Health - October 18, 2017 Category: Consumer Health News Authors: GRETCHEN REYNOLDS Tags: Athletics and Sports Concussions Multiple Sclerosis Sports Injuries Teenagers and Adolescence Source Type: news

Multiple sclerosis: Oligodendrocytes from stemmcells
(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the Heinrich-Heine-University Duesseldorf, Germany, led by Professor Patrick K ü ry (Neurology) and by Professor James Adjaye (Stem Cell Research and Regenerative Medicine) with support from British and Chilean colleagues resulted in a publication on the prospective use of stem cells to generate cell replacement in diseases such as multiple sclerosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

Genomics and Biogen partner to discover new multiple sclerosis treatments
UK-based company Genomics has entered a collaborative deal with US-based biotechnology firm Biogen to discover new treatments for multiple sclerosis (MS). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 16, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Me eting in Paris, France, 25 to 28 October. (Source: Roche Media News)
Source: Roche Media News - October 16, 2017 Category: Pharmaceuticals Source Type: news

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Me eting in Paris, France, 25 to 28 October. (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: All you need to know about dysesthesia
Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms and types here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 15, 2017 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Medical News Today: MS could be reversed with existing allergy drug
An over-the-counter allergy drug may restore function to the nerves damaged by multiple sclerosis, according to a recent phase II trial. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 13, 2017 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

MS risk in children spotted with MRI brain scans
(Yale University) By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and relapses that come with the disease. In a new Yale School of Medicine study, researchers examined MRI brain scans to identify children at high risk of developing MS before symptoms appear, which may lead to earlier diagnosis and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 13, 2017 Category: International Medicine & Public Health Source Type: news

House Ethics Office Says New York Congressman May Have Violated Rules
An inquiry centered on actions by a New York Congressman who is a majority stockholder in a biotech company. (Source: NYT Health)
Source: NYT Health - October 12, 2017 Category: Consumer Health News Authors: KATIE THOMAS and SHEILA KAPLAN Tags: Drugs (Pharmaceuticals) United States Politics and Government Stocks and Bonds Multiple Sclerosis Insider Trading House of Representatives Innate Immunotherapeutics Ltd Price, Thomas E (1954- ) Source Type: news